Complex Dosing, Polypharmacy Common With Interstitial Lung Disease
Patients receiving systemic corticosteroids are at high risk for drug - disease interactions (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - March 14, 2019 Category: Respiratory Medicine Tags: Pharmacy, Pulmonology, Journal, Source Type: news

Complex Dosing, Polypharmacy Common With Interstitial Lung Disease
THURSDAY, March 14, 2019 -- Polypharmacy and complex medication regimens are common in patients with interstitial lung disease (ILD), according to a study published online Feb. 20 in Respirology. Yet H. Khor, M.B.B.S., Ph.D., from the University of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 14, 2019 Category: Pharmaceuticals Source Type: news

COPD, ILD Patients May Not Benefit From Bilateral Lung Transplant Listing
MONDAY, March 4, 2019 -- While an unrestricted listing strategy does not seem to impact overall survival among patients with chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD) awaiting lung transplant, it may increase... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 4, 2019 Category: Pharmaceuticals Source Type: news

Pulmonary Disease Rates High in Lupus
(MedPage Today) -- Interstitial lung disease most common among incident, prevalent cases (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 8, 2019 Category: Primary Care Source Type: news

After the Product-Centric Medical Industry – What’s Next?
For decades, the medical device industry has reaped rewards by providing new technologies and solutions that improve healthcare delivery. Now, more than 8000 new medical devices enter the U.S. market each year1 as the industry faces sweeping changes that will not only impact the life cycle of many existing products, but also future innovations. New payment models, patients replacing physicians as stewards of their care, a changing regulatory framework, and data as a central solution to implement these strategies are all converging trends requiring medical device makers to prepare their organizations to adapt to...
Source: MDDI - January 25, 2019 Category: Medical Devices Authors: David Hahn Tags: Digital Health Source Type: news

Bittersweet Ending to Asbestos Cleanup in Libby, Montana
The asbestos cleanup of Libby, Montana, is coming to a celebrated close. The U.S. Environmental Protection Agency will soon end the largest, longest-running asbestos cleanup project in American history. It’s a bittersweet ending to what is left behind. The 19-year, $600 million EPA Superfund project aimed to right the wrongs created by the shuttered W.R. Grace and Co. vermiculite mine. Once the lifeblood of the community, it also became a cold-hearted killer. Although the mine was closed almost 30 years ago, health officials have since documented more than 400 deaths linked to asbestos-related diseases such as mes...
Source: Asbestos and Mesothelioma News - December 11, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Does She Have SCID?
Discussion Severe-combined immunodefiency (SCID) is actually a group of inherited disorders with an absence or dysfunction of T, B and NK cells that results in severe dysfunction of the immune system. SCID is a primary immunodeficiency. SCID was thought to be a rare disorder but with the advent of neonatal screening the incidence in the US general population is estimated at ~1 in 58,000 live births, but with numbers higher or lower depending on the specific population. Patients often have failure to thrive, oral candidiasis, and diarrhea as infants as well as a variety of infectious diseases. They can also have interstit...
Source: PediatricEducation.org - December 3, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Paradoxical Development of Panuveitis and Granulomatous Interstitial Lung Disease Associated with Adalimumab Therapy for Psoriasis
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 19, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news

CU researchers find common genetic link in lung ailments
(University of Colorado Anschutz Medical Campus) An international research team led by members of the University of Colorado School of Medicine faculty has identified a genetic connection between rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis. The findings are published in the current issue of the New England Journal of Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 22, 2018 Category: International Medicine & Public Health Source Type: news

Medical News Today: How can psoriasis affect the lungs?
Psoriasis causes widespread inflammation that can affect the skin and several organ systems. A person with psoriasis may experience lung-related complications, including lung fibrosis and interstitial lung disease. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 1, 2018 Category: Consumer Health News Tags: Psoriasis Source Type: news

Low Vitamin D Levels Tied to Interstitial Lung Disease
Findings include both high - attenuation areas, interstitial lung abnormalities on scans (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - September 21, 2018 Category: Respiratory Medicine Tags: Family Medicine, Internal Medicine, Pulmonology, Journal, Source Type: news

Low Vitamin D Levels Tied to Interstitial Lung Disease
FRIDAY, Sept. 21, 2018 -- Vitamin D deficiency is independently associated with subclinical interstitial lung disease (ILD) and its progression, according to a study recently published in the Journal of Nutrition. Samuel M. Kim, M.D., from the Johns... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 21, 2018 Category: Pharmaceuticals Source Type: news

Medical News Today: What to know about rheumatoid lung disease
Rheumatoid lung disease happens when rheumatoid arthritis (RA) affects a person's lungs. Lung issues arise in around 10 percent of people with RA, including interstitial lung disease or lung nodules. In this article, we give an overview of rheumatoid lung disease, including symptoms, treatments, and life expectancy. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 28, 2018 Category: Consumer Health News Tags: Rheumatoid Arthritis Source Type: news

Researchers Find Link Between Vitamin D and Asbestosis
This study was not designed to explain whether supplementing with vitamin D will protect against asbestosis. This new research also does not examine if taking vitamin D will slow down the progression of existing ILD. Still, there are a lot of good reasons to pay attention to the sunshine vitamin. Regardless of whether a person has been exposed to asbestos, no one should ignore very low vitamin D levels. People already diagnosed with an asbestos-related cancer, may benefit from a quick check of vitamin D levels. According to the medical literature, up to 80 percent of people with cancer may be vitamin D deficient. People ca...
Source: Asbestos and Mesothelioma News - July 16, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Vitamin D Deficiency Could Be Lung Disease Risk
MONDAY, June 25, 2018 -- Low levels of vitamin D are associated with an increased risk of a disease that causes lung inflammation and scarring, researchers say. About 200,000 cases of interstitial lung disease (ILD) are diagnosed each year in the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 25, 2018 Category: General Medicine Source Type: news

Low vitamin D linked to scarring lung disease
Lower than normal levels of vitamin D in the blood were linked to increased risk of early interstitial lung disease, according to an analysis of a new study. (Source: Health News - UPI.com)
Source: Health News - UPI.com - June 19, 2018 Category: Consumer Health News Source Type: news

Low vitamin D levels associated with scarring lung disease
(Johns Hopkins Medicine) Reviewing medical information gathered on more than 6,000 adults over a 10-year period, Johns Hopkins researchers have found that lower than normal blood levels of vitamin D were linked to increased risk of early signs of interstitial lung disease (ILD). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 19, 2018 Category: International Medicine & Public Health Source Type: news

Barriers to Timely Diagnosis of Interstitial Lung Disease Barriers to Timely Diagnosis of Interstitial Lung Disease
What are the barriers patients with interstitial lung diseases may face in obtaining a timely and accurate diagnosis?BMC Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 11, 2018 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease
Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease (SSc-ILD). The FDA's Fast Track designation facilitates the development of new therapies that treat serious conditions and fulfill an unmet medical need in an effort to get treatments to those in need sooner. (Source: World Pharma News)
Source: World Pharma News - March 19, 2018 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

Lung Disease Common in Late-Onset SLE (CME/CE)
(MedPage Today) -- Rates of interstitial lung disease more than doubled (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 6, 2018 Category: Primary Care Source Type: news

Medical News Today: What to know about interstitial lung disease
A look at interstitial lung disease, a group of diseases that make it difficult to get enough oxygen. Included is detail on types and complications. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 18, 2018 Category: Consumer Health News Tags: Pulmonary System Source Type: news

Bellerophon brings inhaled nitric oxide into Ph2 pulmonary hypertension trial
Bellerophon Therapeutics (NSDQ:BLPH) has enrolled the first patient in a Phase IIb study assessing its INOpulse device in patients with pulmonary hypertension due to interstitial lung disease. The company’s placebo-controlled study is slated to evaluate the safety and efficacy of pulsed, inhaled nitric oxide in patients with PH-ILD, including those with idiopathic pulmonary fibrosis, Bellerophon reported. Get the full story at out sister site, Drug Delivery Business News. The post Bellerophon brings inhaled nitric oxide into Ph2 pulmonary hypertension trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 4, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Bellerophon Therapeutics Source Type: news

Exercise Training in Interstitial Lung Disease Exercise Training in Interstitial Lung Disease
Pulmonary rehabilitation programs including exercise training may be an effective intervention in stable patients with interstitial lung disease.Thorax (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 26, 2017 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news

Warning of too few specialist nurses for incurable lung disease
A lack of access to specialist nurses is an important factor contributing to a crisis in care for patients with interstitial lung disease (ILD), according to a charity report. (Source: Nursing Times)
Source: Nursing Times - September 18, 2017 Category: Nursing Source Type: news

Interstitial Pneumonitis (Interstitial Lung Disease)
Title: Interstitial Pneumonitis (Interstitial Lung Disease)Category: Diseases and ConditionsCreated: 11/10/2014 12:00:00 AMLast Editorial Review: 8/8/2017 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - August 8, 2017 Category: Respiratory Medicine Source Type: news

Occupational Exposures Linked to Interstitial Lung Disease
Job exposure matrix score increase in vapors, gas, dust, fumes exposure ups high attenuation areas (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - August 7, 2017 Category: Respiratory Medicine Tags: Pulmonology, Journal, Source Type: news

FDA accepts Bellerophon ’s Phase IIb design for INOpulse in PH-ILD
The US Food and Drug Administration (FDA) has accepted Bellerophon Therapeutics ’ study design for the Phase IIb clinical trial of INOpulse in patients with Interstitial Lung Disease (ILD) associated pulmonary hypertension (PH). (Source: Drug Development Technology)
Source: Drug Development Technology - August 4, 2017 Category: Pharmaceuticals Source Type: news

Interstitial Lung Disease Boosts Mortality in RA (CME/CE)
(MedPage Today) -- New study highlights need for early diagnosis, better treatments (Source: MedPage Today Pulmonary)
Source: MedPage Today Pulmonary - June 27, 2017 Category: Respiratory Medicine Source Type: news

National Jewish Health and partner to establish respiratory institute in Philadelphia
Denver's National Jewish Health, which focuses on respiratory care, is teaming up with Philadelphia hospital system Jefferson Health to create the Jane and Leonard Korman Respiratory Institute in Philadelphia. The institute — expected to open this summer — is being created to define the best practices for treating and researching pulmonary diseases and related disorders. Such conditions include chronic obstructive pulmonary disease, asthma, interstitial lung disease, sarcoidosis, and infectious… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 26, 2017 Category: Pharmaceuticals Authors: John George Source Type: news

National Jewish Health and partner to establish respiratory institute in Philadelphia
Denver's National Jewish Health, which focuses on respiratory care, is teaming up with Philadelphia hospital system Jefferson Health to create the Jane and Leonard Korman Respiratory Institute in Philadelphia. The institute — expected to open this summer — is being created to define the best practices for treating and researching pulmonary diseases and related disorders. Such conditions include chronic obstructive pulmonary disease, asthma, interstitial lung disease, sarcoidosis, and infectious… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 26, 2017 Category: Biotechnology Authors: John George Source Type: news

Jefferson, Denver specialty hospital to establish respiratory institute in Philadelphia
Jefferson Health is teaming up with National Jewish Health, a 118-year-old specialty hospital in Denver that focuses on respiratory care, to create the Jane and Leonard Korman Respiratory Institute in Philadelphia. The institute — expected to open this summer — is being created to define the best practices for treating and researching pulmonary diseases and related disorders. Such conditions include chronic obstructive pulmonary disease, asthma, interstitial lung disease, sarcoidosis, and infectious… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 26, 2017 Category: Pharmaceuticals Authors: John George Source Type: news

Jefferson, Denver specialty hospital to establish respiratory institute in Philadelphia
Jefferson Health is teaming up with National Jewish Health, a 118-year-old specialty hospital in Denver that focuses on respiratory care, to create the Jane and Leonard Korman Respiratory Institute in Philadelphia. The institute — expected to open this summer — is being created to define the best practices for treating and researching pulmonary diseases and related disorders. Such conditions include chronic obstructive pulmonary disease, asthma, interstitial lung disease, sarcoidosis, and infectious… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 26, 2017 Category: Biotechnology Authors: John George Source Type: news

Boehringer begins enrolment in Phase III trial of nintedanib for fibrosing lung diseases
US-based Boehringer Ingelheim Pharmaceuticals has begun patient enrolment in the Phase III progressive fibrosing interstitial lung disease (PF-ILD) clinical trial of nintedanib to treat various progressive fibrosing lung diseases, excluding idiopathi … (Source: Drug Development Technology)
Source: Drug Development Technology - April 21, 2017 Category: Pharmaceuticals Source Type: news

Clinical Course of Anti-EJ Antibody-Related Lung Disease Clinical Course of Anti-EJ Antibody-Related Lung Disease
A new study describes the clinical features of patients with anti-glycyl-tRNA synthetase antibody-positive interstitial lung disease.BMC Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 24, 2017 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - September 9, 2016 Category: Research Source Type: news

Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 7, 2016 Category: Research Source Type: news

Consultation on specialised services clinical commissioning policies
NHS England has launched a 30 day public consultation on two proposed new clinical commissioning policies for specialised services – specifically Rituximab for the treatment of primary Sjogren’s syndrome in adults, and Rituximab in connective tissue disease associated interstitial lung disease in adults. (Source: NHS Networks)
Source: NHS Networks - May 3, 2016 Category: UK Health Source Type: news

Anti-fibrotic peptide shows early promise against interstitial lung disease
The M10 peptide reduces collagen production and reverses fibrotic damage due to systemic sclerosis (SSc)-related interstitial lung disease (ILD), preclinical findings suggests. ILD is one of the deadliest complications of SSc, a chronic autoimmune disease characterized by vasculopathy, autoimmunity, and excessive collagen production and deposition. Lung fibrosis carries a high risk of morbidity/mortality in SSc patients. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 13, 2016 Category: Science Source Type: news

Anti-fibrotic peptide shows early promise against interstitial lung disease
(Medical University of South Carolina) Investigators at the Medical University of South Carolina report preclinical findings showing that the M10 peptide reduces collagen production and reverses fibrotic damage due to systemic sclerosis (SSc)-related interstitial lung disease (ILD) in the April 2016 issue of Translational Research. ILD is one of the deadliest complications of SSc, a chronic autoimmune disease characterized by vasculopathy, autoimmunity, and excessive collagen production and deposition. Lung fibrosis carries a high risk of morbidity/mortality in SSc patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 13, 2016 Category: Global & Universal Source Type: news

Interstitial Lung Disease Tied to All-Cause Death Risk (CME/CE)
(MedPage Today) -- Specific set of lung abnormalities may be especially problematic for older patients (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - February 17, 2016 Category: Geriatrics Source Type: news

RheumNow: Interstitial Lung Disease Not Increased With Biologics
(MedPage Today) -- New study explores risk of ILD in RA patients on biologics (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - November 28, 2015 Category: Primary Care Source Type: news

Promising treatment for scleroderma-related interstitial lung disease
Mycophenolate mofitil is as effective as cyclophosphamide in treating interstitial lung disease in people with scleroderma, according to new research. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 8, 2015 Category: Science Source Type: news

VIDEO: MMF equals cyclophosphamide’s efficacy in sclerodermal lung disease
MONTREAL – The immunosuppressant mycophenolate mofetil worked as effectively as cyclophosphamide for treating scleroderma-related interstitial lung disease while being better tolerated and causing fewer adverse effects in a multicenter, head-to-head comparison with 142 randomized patients. “The... (Source: Skin and Allergy News)
Source: Skin and Allergy News - November 3, 2015 Category: Dermatology Source Type: news

Fewer Mycophenolate Adverse Events in Scleroderma Lung StudyFewer Mycophenolate Adverse Events in Scleroderma Lung Study
Results from the first clinical trial comparing mycophenolate with cyclophosphamide suggest that treatment options for scleroderma-related interstitial lung disease are expanding. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 2, 2015 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

RA: Lung Disease Risk Tracks Biomarkers (CME/CE)
(MedPage Today) -- Standard RA biomarkers appear to raise risk of interstitial lung disease (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - August 24, 2015 Category: Geriatrics Source Type: news

Baseline CT scans predict lung fibrosis in SSc
Patients with newly diagnosed systemic sclerosis should have a high-resolution lung CT and pulmonary function tests, because when assessed together, their findings identify patients at high risk of interstitial lung disease, researchers say. In a study of 305 patients with systemic sclerosis... (Source: Skin and Allergy News)
Source: Skin and Allergy News - May 2, 2015 Category: Dermatology Tags: CME-candidate IMN News RHEUM News RHEUM Lupus/Connective Tissue Diseases CHEST Pulmonary Medicine CHEST Clinical News CHEST News FPN News Source Type: news

Interstitial Lung Disease
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - April 22, 2015 Category: Journals (General) Source Type: news

Interstitial Lung Disease in Systemic SclerosisInterstitial Lung Disease in Systemic Sclerosis
How often should systemic sclerosis patients be screened for interstitial lung disease? Annals of the Rheumatic Diseases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 3, 2015 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Interstitial lung disease is significant risk factor for lung inflammation
Pretreatment interstitial lung disease is a significant risk factor for developing symptomatic and severe radiation pneumonitis in stage I non-small cell lung cancer patients treated with stereotactic body radiation therapy alone, researchers say. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 10, 2014 Category: Science Source Type: news